In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “
”) confirms that, as of the close of business on July 11, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 451,716,767 ordinary shares, par value US$0.20 per share (the “
”). The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00B68SQD29.
The Company confirms that, as of the close of business on July 11, 2014, there were outstanding 1,646,741 restricted share units (the “
Restricted Share Units
”) and 13,514,154 options to purchase Ordinary Shares (the “
”) granted by the Company. Upon vesting, each Restricted Share Unit entitles the holder to receive one Ordinary Share and each Share Option entitles the holder to purchase one Ordinary Share at the applicable exercise price.
The Company also confirms that, as of the close of business on July 11, 2014, there were outstanding performance share units (the “
Performance Share Units
”) entitling holders to receive up to a maximum of 2,207,292 Ordinary Shares upon vesting, assuming satisfaction of the applicable performance criteria at maximum performance.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit
to learn more about our business.
The number of Ordinary Shares capable of being issued in respect of the Restricted Share Units and Performance Share Units described in this announcement includes the Ordinary Shares capable of being issued upon the vesting of the applicable dividend equivalent units attaching to the respective Restricted Share Units and Performance Share Units.